Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
11
×
boston blog main
life sciences
national blog main
clinical trials
boston top stories
cancer
san francisco blog main
fda
national top stories
boston
ipo
new york blog main
cancer drugs
san diego blog main
san francisco top stories
sanofi
deals
europe blog main
investing
new york top stories
san diego top stories
third rock ventures
venture capital
akouos
biogen
boulder/denver blog main
boulder/denver top stories
deerfield management
detroit blog main
detroit top stories
drug discovery
dyne therapeutics
europe top stories
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
myotonic dystrophy type 1
national
What
ipo
11
×
medicines
11
×
drug
new
therapeutics
bio
cancer
developing
genetic
million
research
biotech
brings
company
covid
diseases
dyne
experimental
fda
lead
muscle
plans
proteins
raised
rare
reach
revolution
roundup
targets
acquisitions
activity
affects
ago
americans
analysis
announced
approvals
approved
based
begin
Language
unset
Current search:
biotech
×
ipo
×
medicines
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds